Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy update | O…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization and review

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines which oncology medications and supportive agents require review by Evolent/New Century Health (NCH) for Fidelis Care (Wellcare) Medicare members, and lists HCPCS/J-codes and pharmacy agents in scope and out-of-scope items. Affects participating providers dispensing or administering oncology drugs in outpatient, office, or pharmacy settings.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization and review
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2024
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent/New Century Health for review prior to dispensing or administration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+HCPCS/CPT/J-codes listed requiring review
    ListPreferred biosimilars provided
    ListOut-of-scope items

    Coverage Criteria

    Prior review required

    Covered when ALL of the following are met

    NCH review requirement: The oncology medication or supportive agent is listed in the policy and the requested drug(s) are to be dispensed at a pharmacy OR administered in a physician's office, outpatient hospital, or ambulatory setting; the provider submits the entire oncology regimen and supporting clinical information to Evolent (New Century Health) for review prior to dispensing or administration

    Applies to members of all ages and includes medical- and pharmacy-benefit agents as indicated; clinical trials may be submitted

    Do NOT submit the following to New Century Health (NCH) for review: Antibiotics; Bone marrow, stem cell transplants, and CAR‑T cell therapy; controlled substances (e.g., morphine); equipment requests (infusion pumps); genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins.

    Coding and Billing (HCPCS, J‑codes, Pharmacy)

    Covered HCPCS/J Codes (excerpt)HCPCSCovered
    J1434FOSAPREPITANT (FOCINVEZ)
    J1442FILGRASTIM G-CSF 1 MCG INJ
    J1447TBO-FILGRASTIM
    J1448TRILACICLIB INJ
    J1449EFLAPEGRASTIM-XNST INJECTION
    J1453FOSAPREPITANT INJ
    J1454FOSNETUPITANT/PALONOSETRON
    J1456FOSAPREPITANT INJ
    J1627GRANISETRON HCL ER INJ
    J1930LANREOTIDE
    1–10 of 11
    1/2
    Covered HCPCS/J Codes (continued excerpt)HCPCSCovered
    J9000DOXORUBICIN HCL INJ
    J9050CARMUSTINE
    J9216INTERFERON GAMMA 1B
    J9301OBINUTUZUMAB
    J9312RITUXIMAB INJECTION
    J9317SACITUZUMAB GOVITECAN-HZIY
    J9324PEMETREXED (PEMRYDI RTU)
    J9355TRASTUZUMAB INJ
    J9311RITUXIMAB AND HYALURONIDASE HUMAN
    J2562PLERIXAFOR INJECTION
    Q-Codes / HCPCS Labelling (examples)HCPCSCovered
    Q5106EPOETIN ALFA-EPBX (RETACRIT BIOSIMILAR)
    Q5113TRASTUZUMAB-DTTB
    Q5126BEVACIZUMAB-MALY
    Q5127PEGFILGRASTIM-FPGK
    Pharmacy benefit / oral oncology codes and J8999 mappingsHCPCSCovered
    J8999OTHER ANTINEOPLASTIC AGENT (multiple oral agents listed under J8999 mapping)
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL
    J8530CYCLOPHOSPHAMIDE ORAL
    Covered C-Codes (select)CPTCovered
    C9142BEVACIZUMAB-MALY
    C9146MIRVETUXIMAB SORAVTANSINE-GYNX
    C9147TREMELIMUMAB-ACTL INJECTION
    C9148TECLISTAMAB-CQYV INJECTION
    C9155EPCORITAMAB-BYSP
    C9163INJ TALQUETAMAB-TGVS
    C9165INJ ELRANATAMAB-BCMM
    C9293GLUCARPIDASE
    inv-08: Submission requirement — Entire oncology regimen must be submitted
    RequirementSubmit the entire oncology regimen to Evolent (New Century Health) prior to dispensing or administration; omitting any part may result in a denial.
    When to submitFor all participating providers: before dispensing at a pharmacy or administering in a physician's office, outpatient hospital, or ambulatory setting for members of all ages.
    How to submitVia NCH web portal (my.newcenturyhealth.com) or by phone (1-888-999-7713, option 1).
    Applies toOncology medications and supportive agents regardless of benefit assignment (medical or pharmacy) as listed in the policy.

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Oncology medications and supportive agents (medical or pharmacy benefit) require review by Evolent (formerly New Century Health, NCH) for participating providers prior to dispensing or administration. Submit the entire oncology regimen to Evolent/NCH — omissions may result in a denial. Requests may be submitted via the NCH web portal (my.newcenturyhealth.com) or by phone at 1-888-999-7713, option 1. Non‑participating providers must submit requests to the plan via fax: 1-844-235-5090 (formerly 1-877-882-5892). Clinical trial medications may also be submitted for review.

    • Submit the entire oncology regimen to Evolent/NCH; partial regimen submissions may be denied.
    • Participating providers: use NCH web portal (my.newcenturyhealth.com) or call 1-888-999-7713, option 1.
    • Non‑participating providers: submit to the plan via fax 1-844-235-5090.
    Note

    Scope and Preferred Agents

    The following lists summarize scope and preferred biosimilars that are managed via Evolent/NCH review. Do NOT submit the items listed as out-of-scope to NCH (e.g., inpatient drug requests, surgeries, stem cell transplants, CAR-T, genetic testing, hemophilia drugs, controlled substances, equipment requests, radiopharmaceuticals, immune globulins, sickle cell therapies). Preferred biosimilar agents for certain oncology-related indications are identified (providers should still submit requests for the preferred agent to NCH for clinical review).

    Initial Therapy Criteria

    Initial authorization

    Initial coverage step

    Initial review: Provider must submit the entire oncology regimen and supporting clinical information to Evolent (New Century Health) via the NCH web portal (my.newcenturyhealth.com) or by phone prior to dispensing or administration

    If provider is non-participating with NCH, submit prior authorization request to the plan via fax as specified in the policy

    Step Therapy and Preferred Agents

    Drug class / agent(s)Preferred biosimilar(s) / benefit assignmentProvider action
    Erythropoiesis-stimulating agentsMedical benefit: Retacrit (if unavailable due to shortage: Epogen); Pharmacy benefit: ProcritSubmit request for the preferred agent to New Century Health (NCH) for review prior to dispensing or administration
    Trastuzumab (HER2-directed therapies)Medical benefit: Trazimera; Pharmacy benefit: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, TrazimeraProviders should send requests for the preferred trastuzumab product/biosimilar to NCH for review
    Bevacizumab (anti‑VEGF)Medical benefit: Mvasi, Zirabev; Pharmacy benefit: Avastin, Mvasi, ZirabevSubmit preferred bevacizumab product (including biosimilars) to NCH for review
    Hematopoietic agents / filgrastim biosimilarsMedical & Pharmacy benefit: ZarxioSend request for Zarxio (or other listed hematopoietic agent) to NCH for review
    RituximabMedical benefit: Ruxience, Truxima; Pharmacy benefit: Riabni, Rituxan, Rituxan Hycela, Ruxience, TruximaProviders must submit requests for the preferred rituximab product to NCH for review

    Site of Care Requirements

    Prior Authorization

    Prior review required for office administration

    Prior review by NCH is required before administration of listed oncology medications and supportive agents in physician offices, outpatient hospitals, or ambulatory settings.

    Prior Authorization

    Prior review required for infusion center administration

    Prior review by NCH is required before administration of listed oncology medications and supportive agents at infusion centers (physician office, outpatient hospital, ambulatory settings).

    Billing Rule

    Pharmacy benefit agents still require NCH review

    Biosimilar Preferences and Examples

    Billing Rule

    Erythropoiesis‑stimulating agent benefit assignment examples

    Benefit assignment example: for erythropoiesis‑stimulating agents Retacrit is the medical‑benefit example (with Epogen noted if Retacrit is unavailable due to shortage); Procrit is listed as the pharmacy benefit product.

    Billing Rule

    Trastuzumab reference products and pharmacy examples

    Trastuzumab benefit assignment examples: Trazimera is listed as the medical benefit reference product; Herceptin and listed trastuzumab biosimilars are noted for the pharmacy benefit.

    Background

    Oncology medications and supportive agents include a broad range of infused and oral anticancer drugs, hematopoietic growth factors, antiemetics, and supportive biologics. This policy identifies agents that require review by Evolent/New Century Health (NCH) to confirm indication appropriateness and to determine benefit routing (medical vs. pharmacy). Preferred biosimilar agents are listed for certain classes to guide benefit assignment, but providers must still submit requests for the preferred agent to NCH for review.

    Definitions

    inv-16: Participating provider — A provider who has an established relationship with the plan and must submit oncology medication requests to Evolent (NCH) for review pri...
    DefinitionA participating provider has an established relationship with the plan and must submit oncology medication requests to Evolent (New Century Health) for review prior to dispensing or administration.
    When to use NCHParticipating providers must send requests for oncology medications and supportive agents before dispensing at a pharmacy or administering in office/outpatient/ambulatory settings.
    Submission methodsUse NCH web portal (my.newcenturyhealth.com) or call 1-888-999-7713, option 1 to submit requests.
    inv-17: Non-participating provider — A provider not participating with NCH; must submit prior authorization requests directly to the plan via fax as specified.
    DefinitionA non-participating provider does not participate with NCH and must submit prior authorization requests directly to the plan via fax.
    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization and review
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2024
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent/New Century Health for review prior to dispensing or administration.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing (HCPCS, J‑codes, Pharmacy)Provider Actions and RequirementsInitial Therapy CriteriaStep Therapy and Preferred AgentsSite of Care RequirementsBiosimilar Preferences and ExamplesBackgroundDefinitions
    • Out of scope (do NOT submit to NCH): Antibiotics; Bone marrow/stem cell transplants; CAR-T cell therapy; Controlled substances; Equipment (infusion pumps); Genetic lab testing; Hemophilia drugs; Inpatient drug requests; Inpatient radiation/chemotherapy; Iron preparations; Radiopharmaceuticals; Surgeries; Sickle cell diagnoses/therapies; Immune globulins.
    • Preferred biosimilars (submit preferred agent to NCH for review): Erythropoiesis-stimulating agents (Medical: Retacrit; Pharmacy: Procrit), Trastuzumab (Medical: Trazimera; Pharmacy: Herceptin and biosimilars), Bevacizumab (Medical: Mvasi, Zirabev; Pharmacy: Avastin and biosimilars), Hematopoietic agents (Zarxio), Rituximab (Medical: Ruxience, Truxima; Pharmacy: Riabni, Rituxan, others), Bone agents and others as specified in the policy.
    Denial Risk

    Complete Regimen Submission Required

    All oncology regimen components (all agents, supportive drugs, and related administration codes) must be included in the submission to NCH. Failure to include any part of the regimen when submitting to Evolent/NCH may result in a denial of authorization.

    • Include the entire regimen (all agents and supportive medications) in a single submission to Evolent/NCH.
    • Clinical rationale and indication should be provided to establish medical necessity for each agent.
    Prior Authorization

    Pharmacy Benefit Review

    A secondary list identifies oncology medications/supportive agents that require NCH review when provided via the pharmacy benefit only. Check the plan's code lists (HCPCS/CPT/NDC) and pharmacy benefit rules; if the drug is delivered via pharmacy and appears on the pharmacy-only list, submit to NCH for review.

    • Drugs billed via pharmacy benefit that appear on the pharmacy-only list require NCH review prior to dispensing.
    • Verify benefit pathway (medical vs pharmacy) and submit accordingly to NCH.
    Note

    Biosimilar Preference Notice

    Preferred biosimilar agents for certain oncology-related indications are listed in the policy. Providers should still send requests for the preferred agent to NCH for review and authorization.

    • Examples include preferred agents for trastuzumab, bevacizumab, rituximab, erythropoiesis-stimulating agents, and hematopoietic agents as detailed in the policy lists.

    Certain listed agents are pharmacy benefit only but still require New Century Health review prior to dispensing; providers must submit these pharmacy‑only agents to NCH as indicated in the pharmacy list.

    Fax numberSubmit requests to the plan at: 1-844-235-5090 (new fax as of 10/1/2023; formerly 1-877-882-5892).
    When to faxUse fax submission for prior authorization requests when the provider is not participating with NCH; do not submit these requests to the NCH portal/phone.